Paul McMurrick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul McMurrick has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Rathin Gosavi
Colorectal Unit, Monash Health, Clayton, Victoria, Australia
3 shared publications - Stephen Bell
Department of Colorectal Surgery Cabrini Health Melbourne Victoria Australia
3 shared publications Vignesh Narasimhan
Department of Colorectal Surgery Cabrini Health Melbourne Victoria Australia
2 shared publications- William Teoh
Department of Colorectal Surgery Monash Health Australia
2 shared publications - Mithra Sritharan
Department of Hepatobiliary Surgery, Monash Health, Melbourne, Victoria, Australia
1 shared publication Satish K. Warrier
Division of Cancer Surgery, Division of Cancer Research Peter MacCallum Cancer Centre Melbourne Victoria Australia
1 shared publication
Latest Publications
- 23 June 2026
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 30 (3) , 271-275
Resect first in resectable colorectal liver metastases: recalibrating the default
Perioperative chemotherapy is frequently used for resectable colorectal liver metastases (CRLM), despite persistent uncertainty regarding the extent of its survival benefit. This perspective revisits the evidence supporting this practice and asks whether upfront liver-directed treatment should be more strongly considered in selected patients. A central paradox underpins this debate: although adjuvant chemotherapy improves OS in stage III colon cancer, randomized trials in resectable CRLM have consistently failed to demonstrate an OS advantage for perioperative or adjuvant systemic therapy. Instead, chemotherapy primarily appears to delay recurrence while exposing patients to potential harms. These harms include treatment-related hepatic injury, increased perioperative morbidity, and, in some cases, progression during induction therapy that may preclude curative resection. Several explanations may account for this discrepancy, including clonal selection of resistant disease, the influence of the hepatic metastatic microenvironment, and the availability of salvage local therapy at recurrence. Nevertheless, systemic therapy remains relevant in selected patients with technically or biologically complex disease, such as those requiring staged liver surgery, downsizing for resectability, or treatment sequencing in synchronous primary and liver disease. Additionally, thermal ablation is emerging as a valid early liver-directed option for carefully selected small-volume metastases. Looking forward, circulating tumor DNA and other molecular tools may better identify the subgroup most likely to benefit from perioperative treatment. Treatment sequencing in resectable CRLM should therefore be guided by anatomy, tumour biology, and emerging molecular markers of residual risk, with systemic therapy used selectively rather than as a universal default.
- 23 June 2026
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 30 (3) , 271-275
Resect first in resectable colorectal liver metastases: recalibrating the default
Perioperative chemotherapy is frequently used for resectable colorectal liver metastases (CRLM), despite persistent uncertainty regarding the extent of its survival benefit. This perspective revisits the evidence supporting this practice and asks whether upfront liver-directed treatment should be more strongly considered in selected patients. A central paradox underpins this debate: although adjuvant chemotherapy improves OS in stage III colon cancer, randomized trials in resectable CRLM have consistently failed to demonstrate an OS advantage for perioperative or adjuvant systemic therapy. Instead, chemotherapy primarily appears to delay recurrence while exposing patients to potential harms. These harms include treatment-related hepatic injury, increased perioperative morbidity, and, in some cases, progression during induction therapy that may preclude curative resection. Several explanations may account for this discrepancy, including clonal selection of resistant disease, the influence of the hepatic metastatic microenvironment, and the availability of salvage local therapy at recurrence. Nevertheless, systemic therapy remains relevant in selected patients with technically or biologically complex disease, such as those requiring staged liver surgery, downsizing for resectability, or treatment sequencing in synchronous primary and liver disease. Additionally, thermal ablation is emerging as a valid early liver-directed option for carefully selected small-volume metastases. Looking forward, circulating tumor DNA and other molecular tools may better identify the subgroup most likely to benefit from perioperative treatment. Treatment sequencing in resectable CRLM should therefore be guided by anatomy, tumour biology, and emerging molecular markers of residual risk, with systemic therapy used selectively rather than as a universal default.
- Open Access
- 10 April 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (7-8) , 1818-1821
Training for Rectal Resection in the Era of Total Neoadjuvant Therapy and Organ Preservation: Safeguarding Competence as Operative Casemix Evolves
- 10 April 2026
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (7-8) , 1818-1821
Open AccessTraining for Rectal Resection in the Era of Total Neoadjuvant Therapy and Organ Preservation: Safeguarding Competence as Operative Casemix Evolves
- Open Access
- 8 August 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (9) , 1666-1667
Exercise as Adjuvant Therapy in Colon Cancer: Implications From the CHALLENGE Trial
- 8 August 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 95 (9) , 1666-1667
Open AccessExercise as Adjuvant Therapy in Colon Cancer: Implications From the CHALLENGE Trial